In visceral leishmaniasis, an intracellular protozoan infection which targets macrophages in the liver, spleen, and bone marrow, successful experimental host defense is T-cell (Th1 cell) dependent, requires T-cell-and macrophage-activating cytokines, and is expressed in the tissues by granulomatous inflammation (23, 24) . While multiple cytokines enable normal BALB/c and C57BL/6 mice to acquire resistance to visceral Leishmania donovani infection (6, 23, 24, 34) , interleukin 12 (IL-12) and gamma interferon (IFN-␥) play particularly prominent roles. IL-12 likely drives the Th1 cell-associated mechanism and induces IFN-␥, both cytokines direct T cells and blood monocytes into granulomas at parasitized tissue foci, and IFN-␥ activates effector monocytes and macrophages to kill intracellular parasites (6, 23, 24, 34) . Endogenous IL-12 and IFN-␥, as well as other cytokines (1, 29) , are also required for the leishmanicidal effect of pentavalent antimony (Sb), used as conventional chemotherapy for visceral leishmaniasis (23, 27, 28) .
Efforts to translate the preceding experimental findings into treatment for L. donovani infection have primarily revolved around injecting IFN-␥ or IL-12 or other IFN-␥ inducers (e.g., IL-2 [23] ) or administering agents which reverse suppression of the Th1 cell response (e.g., anti-IL-10 receptor monoclonal antibody [MAb] ) (30, 31) . These treatments produce leishmanicidal activity by themselves and, when combined with Sb, enhance drug efficacy (23, 30, 31 ).
An alternative strategy to therapeutically harness the same Th1 cell mechanism has focused on T-cell costimulation (7, 11, 19, 20) . Optimal T-cell activation, including induction of the antileishmanial Th1 response with secretion of IL-12, IL-2, and IFN-␥, requires second (costimulatory) signals likely delivered via interaction of surface molecules on T cells and antigenpresenting cells (APC) (7, 11, 19, 20, 39, 41) . CD40 ligand [CD40L]-CD40 and CD28-B7 represent two such signal-transducing receptor pathways (38, 40) , active in various forms of experimental leishmaniasis (3, 4, 10, 11, 14, 15, 17, 32, 37, 38) and accessible to manipulation by MAb injection (7, 15, (18) (19) (20) . Depending upon the model, the host, and the timing of MAb administration, receptor manipulation can stimulate Th1 type responses and enhance resistance.
For example, when given prophylactically, injections of agonist anti-CD40 MAb successfully curtail cutaneous L. major infection in susceptible BALB/c mice, an effect mediated by APC-secreted IL-12 and downstream T-cell-derived IFN-␥ (7). Similarly, MAb-induced blockade of cytotoxic T lymphocyte antigen-4 (CTLA-4), an inhibitory receptor which limits CD28-B7 costimulation (15, 19, 20, 40) , can also enhance IL-12 production and IFN-␥-mediated events (20) . While anti-CTLA-4 treatment produces variable effects and can exacerbate cutaneous L. major infection (10, 15) , anti-CTLA-4 is active both prophylactically and therapeutically against visceral L. donovani infection (20) . In vitro studies with L. chagasi, another agent of visceral leishmaniasis, also support the antileishmanial effect of MAb blockade of either T-cell-expressed CTLA-4 or its B7 ligands on APC (10, 11) .
Increased levels of endogenous IL-12 and/or IFN-␥ would be expected to enhance antileishmanial defense and strengthen the host response to Sb chemotherapy (20, 23) . Therefore, in this study, anti-CD40 was used as an agonist to ligate CD40 and trigger IL-12 secretion (5, 14, 33, 39) while anti-CTLA-4 was used to block negative signaling and maintain CD28-B7-dependent T-cell activation and cytokine secretion (15, 20, 41, 43) . We reasoned that in addition to producing activity by itself in the case of established L. donovani infection (20) , MAb-induced modulation of T-cell costimulatory mechanisms could also be coupled with Sb in an immunochemotherapeutic regimen.
RESULTS

CD40L
and anti-CD40 in defense against L. donovani. CD28-B7 signaling has already been shown to be active in experimental L. donovani infection since manipulation of this pathway by blockade of CTLA-4 or one of its B7 ligands increased Th1 type cytokine expression, promoted granuloma formation, and reduced liver parasite burdens (19, 20) . To determine whether the CD40L-CD40 mechanism can mediate a similar effect, we first challenged CD40L
Ϫ/Ϫ mice with L. donovani and then treated parasitized normal mice with agonist anti-CD40 MAb. In the latter experiments, anti-CTLA-4 was tested in parallel. CD40L-deficient mice. As shown in Fig. 1 , wild-type C57BL/6 mice controlled L. donovani infection after week 3, demonstrating a Th1 cell type-dependent response which requires IL-12 and IFN-␥ (6, 27, 28, 34, 40) . In contrast, CD40L Ϫ/Ϫ mice developed high-level, nonresolving liver infections. Since CD40L-CD40 interaction is a primary stimulus for IL-12 generation by APC (5, 14, 33, 39, 41) , the failure to control L. donovani infection likely involved deficient Th1 cell type responses. In one of the experiments with results shown in Fig. 1 , sera (from three to four mice per group) were available for cytokine measurement before (day 0) and on day 21 after infection. In wild-type C57BL/6 mice, levels of IL-12p40 increased from 3.0 Ϯ 0.1 to 8.1 Ϯ 0.4 ng/ml and those of IFN-␥ increased from 0.01 Ϯ 0.01 to 0.25 Ϯ 0.11 ng/ml. In CD40L Ϫ/Ϫ mice, corresponding day 0 and day 21 values for IL-12p40 were 1.9 Ϯ 0.3 and 2.8 Ϯ 0.3 ng/ml and those for IFN-␥ were 0 (Ͻ6 pg/ml) and 0.01 Ϯ 0.01 ng/ml. Thus, on day 21, when liver parasite burdens in control and deficient mice had clearly diverged ( Fig. 1 (4, 17, 37) . The tissue correlate of the IL-12-and IFN-␥-driven response, granuloma assembly (24) , was also impaired in CD40L-deficient mice. In livers of wild-type C57BL/6 mice, granulomas were forming by week 2 at 89% Ϯ 3% of parasitized foci and were developed (mature) at 92% Ϯ 5% of foci by week 4 ( Fig. 2A) . In CD40 Ϫ/Ϫ mice, this response was essentially absent at week 2 and barely evident at week 4 ( Fig. 2B) , and then it emerged but remained incomplete. At week 8, 23% Ϯ 6% of infected sites showed no mononuclear cell recruitment; the remainder showed developing (62% Ϯ 7%) or morphologically mature (15% Ϯ 2%) granulomas (Fig. 2C) . However, virtually all of the latter contained large numbers of amastigotes (Fig. 2D) , indicating that granulomas appearing to be structurally intact were nonfunctional in the absence of CD40L.
Anti-CD40-treated mice. To demonstrate the effect of CD40 ligation under intact conditions, wild-type BALB/c mice with established infection were injected with agonist anti-CD40 on day 12. Measurements made on day 21 showed that treatment with 0.25 to 0.5 mg of MAb induced leishmanicidal activity, with Ͼ50% reduction in liver parasite burdens (Fig. 3) . Wildtype C57BL/6 mice responded in a similar fashion (Table 1 ). In addition, the antileishmanial effect of single-dose anti-CD40 persisted beyond day 21 (Fig. 4) .
The anti-CD40 effect was also accompanied by increased IFN-␥ production, as judged by cytokine levels in the serum of BALB/c mice on day 21 (Fig. 5 ). In the same mice, IL-12p40 was already readily detectable in sera on day 12, prior to MAb injection (8.1 Ϯ 1.1 ng/ml; n ϭ 10). Serum IL-12p40 levels increased in anti-CD40-treated mice at day 21; however, the day 21 level (11.1 Ϯ 1.4 ng/ml; n ϭ 10) was not significantly different from that in infected controls treated with rat IgG (7.8 Ϯ 0.8 ng/ml; n ϭ 6 [P ϭ 0.11]). Since increases in serum IL-12 levels (as well as IFN-␥ levels) appear to peak soon after (38) or within 3 to 5 days (F. Heinzel, unpublished data) of anti-CD40 injection, IL-12p40 levels prior to day 21 may have been higher in our experiments. In addition, it is also possible that examination at the infected tissue site (e.g., at developing liver granulomas) would have better demonstrated an anti-CD40 effect on IL-12 expression.
Anti-CD40 MAb treatment also induced the remarkable appearance of numerous, often large focal collections of mononuclear cells (primarily lymphocytes, morphologically) in livers of infected BALB/c ( Fig. 6 and 7 ) and C57BL/6 (data not shown) mice. These collections, not present in infected rat IgG-injected controls, were both perivascular and parenchymal and were, in most instances, densely encased parasitized macrophages ( Fig. 6D ). Anti-CD40 injection also induced some mononuclear cell accumulations in livers of uninfected BALB/c mice (Fig. 7) . However, the numbers and sizes of the collections were considerably greater in infected mice ( Fig. 7B and D), suggesting that anti-CD40-mobilized cells were attracted to sites of developing inflammation and/or parasite replication. In infected mice examined 2 weeks after anti-CD40 injection on day 12, the histologic reaction had begun to recede (data not shown).
Effect of anti-CTLA-4 MAb versus that of anti-CD40 MAb. In the experiments described above, wild-type BALB/c mice were also injected once on day 12 with anti-CTLA-4 MAb. Effects on day 21 mirrored those previously reported for anti-CTLA-4 (20): (i) leishmanicidal activity, which also persisted for Ն2 weeks (Figs. 3 and 4) , (ii) increased IFN-␥ secretion (Fig. 5) , and (iii) some increase in granuloma numbers (1.6-fold increase) and maturity as judged by enhanced epithelioid changes ( Fig. 6E and F) . Serum IL-12p40 levels on day 21 were similar in MAb-treated (9.8 Ϯ 1.7 ng/ml; n ϭ 10) and hamster IgG-injected (10.6 Ϯ 2.1 ng/ml; n ϭ 6) BALB/c mice and not significantly different from pretreatment levels (8.1 Ϯ 1.1 ng/ ml). Anti-CTLA-4 was comparably active in wild-type C57BL/6 mice ( Table 1) and did not induce the mononuclear cell collections observed in livers of anti-CD40-treated mice.
Treatment with anti-CD40 plus anti-CTLA-4. CD40L-CD40 and CD28-B7, linked by induction of B7 expression by CD40 stimulation (5, 8, 13, 39, 41) , also converge functionally since both support Th1 cell-associated responses and stimulate IFN-␥ secretion downstream (39, 41) . Since the initial activating cytokines primarily induced are thought to differ (i.e., IL-12 via CD40 versus IL-2 via CD28) (39, 41, 43) , we tested whether leishmanicidal activity could be increased by triggering both pathways. Wild-type BALB/c mice were injected on day 12 with anti-CD40 (0.25 mg) and 2 h later with anti-CTLA-4 (0.5 mg). Combined treatment did not, however, increase parasite killing on day 21 nor yield additional histologic changes other than those induced by anti-CD40 alone (data not shown).
Host mechanisms in response to anti-CD40 and anti-CTLA-4. In normal BALB/c and C57BL/6 mice, the IL-12-driven Th1 cell response activates macrophages for intracellular L. donovani killing within encircling granulomas (23, 24) . The leishmanicidal mechanism requires IFN-␥ induced by IL-12 and/or IL-2, influxing T cells and blood monocytes, and mononuclear phagocyte secretion of toxic products, largely iNOS-derived reactive nitrogen intermediates (6, 20, 22, 23, 24, 26, 28, 34, 40) . To characterize these host components in responses to anti-CD40 and anti-CTLA-4, we tested mice deficient in cytokine production (IL-12p35 Ϫ/Ϫ and IFN-␥ Ϫ/Ϫ ), monocyte influx (ICAM-1 deficient), and reactive nitrogen intermediate secretion (iNOS Ϫ/Ϫ ) (22, 26, 28, 40) . Leishmanicidal responses. Killing induced by both anti-CD40 and anti-CTLA-4 required endogenous IFN-␥ (Table 1) . Optimal killing also involved IL-12, although both MAbs induced a limited effect in IL-12p35 Ϫ/Ϫ mice. In contrast, anti-CD40 and anti-CTLA-4 were fully active in mice deficient in ICAM-1, and killing was also retained in iNOS Ϫ/Ϫ animals. Mice deficient in the mononuclear phagocyte's auxiliary leishmanicidal mechanism, respiratory burst (phox)-generated toxic oxygen intermediates (26) , were tested next. Phox-deficient mice also showed intact responses to both MAbs (Table 1) Tissue granulomatous responses. Expression of ICAM-1, an endothelial adhesion molecule, is required early on in L. donovani infection (weeks 1 to 4) for monocyte entry into and formation of liver granulomas (22) . Nevertheless, ICAM-1-deficient mice treated on day 12 readily responded to both anti-CD40 and anti-CTLA-4 with mononuclear cell recruitment and assembly (Fig. 8A and B and data not shown) . On day 21, the percentage of infected foci which showed mature granulomas increased from Ͻ10% in rat and hamster IgGtreated mice to 81% Ϯ 4% and 84% Ϯ 6%, respectively. This ICAM-1-independent tissue response may reflect activation of a compensatory mechanism previously demonstrated in these same ICAM-1-deficient mice (22) .
Histologic inspection of livers from cytokine-deficient mice yielded additional information about the actions of anti-CTLA-4 and anti-CD40 and the ways in which their effects differ. In livers of IFN-␥ Ϫ/Ϫ and IL-12p35 Ϫ/Ϫ mice, which fail to show granulomas or any tissue inflammatory reaction in response to L. donovani (28, 34, 39) , anti-CTLA-4 treatment on day 12 had no effect (data not shown). In contrast, in the same IFN-␥ Ϫ/Ϫ mice, anti-CD40 induced both the mononuclear cell accumulations seen in normal mice and developing granulomas at 79% Ϯ 9% of infected liver foci on day 21 ( Fig.  8C and D) . Thus, while IFN-␥ is strictly required for granuloma assembly in intact mice (40) , CD40 ligation (but not CTLA-4 blockade) activated an apparently quiescent mechanism for mononuclear cell recruitment in IFN-␥ Ϫ/Ϫ mice. IL-12 is one inducer of such a compensatory, IFN-␥-independent granuloma-forming pathway (40) . In IL-12p35 Ϫ/Ϫ mice, anti-CD40 treatment had no effect on the absent histologic response (data not shown), suggesting that IL-12 may participate in the anti-CD40-induced IFN-␥-independent effect. Not surprisingly, however, in the absence of IFN-␥ and macrophage activation (23, 24) , granulomas induced by anti-CD40 in IFN-␥ Ϫ/Ϫ mice remained heavily parasitized (Fig. 8E ). Responses to antileishmanial chemotherapy. In the case of L. donovani infection, the leishmanicidal efficacy of Sb chemotherapy also requires host T cells and an intact Th1 cell type response with IL-12 and IFN-␥ secretion (23, 27, 28 ). Sb's efficacy can be enhanced by IFN-␥ either by coadministration in exogenous form or by injection of IL-12 to increase endogenous IFN-␥ production (21, 25, 28) . Therefore, we hypothesized that Sb's effect would be (i) diminished in Th1 cell cytokine-deficient CD40L-deficient mice and (ii) enhanced in normal animals first treated with anti-CD40 or anti-CTLA-4.
The results presented in Table 2 confirm the first hypothesis. Wild-type C57BL/6 animals responded to optimal-dose Sb (500 mg/kg) with killing of 88% of liver amastigotes; identically treated CD40L Ϫ/Ϫ mice failed to show leishmanicidal activity. To demonstrate responsiveness to directly acting chemotherapy which does not require the host Th1 cell response (23, 27, 28) , animals were also treated with AmB. CD40L knockout mice responded normally to this agent (Table 2) . To test the second hypothesis and complete this analysis, we used wild-type BALB/c mice and injected suboptimal doses of MAb on day 12 and low-dose Sb on day 14. Injections were separated by 48 h since Sb's efficacy appears to be enhanced if administered after cytokine effects are established (21, 28, 30) . Results on day 21 indicated no parasite killing by low-dose Sb in animals pretreated with either rat or hamster IgG (Fig. 9) . In contrast, in anti-CD40-or anti-CTLA-4-treated animals, Sb was significantly more active (P Ͻ 0.05) and induced killing of 40 to 50% of amastigotes. A portion of the effect (ϳ10%) was due to MAb by itself (Fig. 9) . However, four-to fivefold increases in killing induced by combination treatment indicated clearly enhanced responsiveness to Sb in the presence of either CD40 ligation or MAb-induced blockade of CTLA-4.
DISCUSSION
The findings in this report extend prior studies of the role and effect of the CD40-CD40L pathway in cutaneous L. major and L. amazonensis infection (3, 4, 7, 10, 14, 15, 17, 32, 37, 38) and of CTLA-4 blockade in L. major and L. donovani infection (10, 15, 20) . Together, our results (i) demonstrate that CD40L is required for control of L. donovani infection, appropriate generation of IL-12p40 and especially IFN-␥, development of functional tissue granulomas, and response to Sb chemotherapy; (ii) identify mechanisms of the therapeutic effect of anti-CD40 MAb in the case of established visceral infection and show that anti-CD40 enhances IFN-␥ and modifies mononuclear cell recruitment to parasitized sites; and (iii) confirm the antileishmanial action of CTLA-4 blockade in the case of L. donovani infection (20) . In addition, our results indicate that both anti-CD40 and anti-CTLA-4 increase the efficacy of chemotherapy (Sb), consistent with effects on the Th1 type cytokine (e.g., IFN-␥) response which primarily regulates Sb's leishmanicidal activity (1, 23, 27) . In the assays we employed, the only meaningful difference between the actions of the two MAbs was the capacity of anti-CD40 to stimulate focal recruitment of inflammatory mononuclear cells and to accomplish this effect in an IFN-␥-independent fashion.
Although induction of granuloma assembly in IFN-␥ Ϫ/Ϫ mice demonstrated an IFN-␥-independent action for anti-CD40, its leishmanicidal activity and that of anti-CTLA-4 required endogenous IFN-␥ and, to a lesser extent, its primary inducer, IL-12 (28) . While anti-CD40 and anti-CTLA-4 both stimulated IFN-␥ production, likely enhancing downstream effector cell mechanisms, parasite killing triggered by these MAbs was nevertheless preserved in mice deficient in either iNOS or phox. This finding was unexpected since anti-CD40 induces macrophage iNOS (42) and iNOS in turn regulates the key leishmanicidal pathway in the IFN-␥-activated macrophage (26) . While a prior study indicated that the phox mechanism by itself was not sufficient to control L. donovani in otherwise untreated iNOS Ϫ/Ϫ mice (26), gene-deficient animals, including iNOS Ϫ/Ϫ and phox Ϫ/Ϫ mice, may express heightened compensatory responses (29, 30, 31) . Thus, it is possible that the efficacy of phox in iNOS Ϫ/Ϫ mice was enhanced by anti-CD40 or anti-CTLA-4 treatment leading to respiratory burst-mediated parasite killing. However, we have not tested anti-CD40 or anti-CTLA-4 in mice deficient in both iNOS and phox (36) ; therefore, it also remains possible that a recently identified but undefined macrophage mechanism independent of both pathways may be involved (36) . Given the intracellular location of L. donovani, the likelihood that anti-CD40 or anti-CTLA-4 stimulated an altogether separate, IFN-␥-dependent mechanism unrelated to macrophage activation seems low.
Anti-CD40 was used here to ligate CD40 and primarily trigger IL-12 secretion by APC, a well-defined effect of signaling through CD40 in dendritic cells (5, 14, 33, 39) . Anti-CTLA-4 was employed to block negative signaling and maintain CD28-B7-dependent T-cell activation and cytokine (e.g., IL-2) secretion (15, 20, 41, 42) . Despite differing modes of action, both MAb-directed immunointerventions would be expected to enhance IFN-␥ production and generally raise the level of T-cell reactivity (9, 15, 20, 34, 37, 38, 40, 42 (8, 12, 32, 35, 43) . Since the preceding experiments were carried out in normal animals in the midst of developing a Th1 cell response, the therapeutic usefulness of anti-CD40 or anti-CTLA-4 is likely predicated on host capacity to satisfactorily produce IL-12 and IFN-␥. In addition, it is also worth noting that CD40 activation and blockade of CTLA-4 have the potential to induce the release of multiple proinflammatory cytokines (7, 16, 39, 41) ; thus, although not seen in our model, MAb treatment, especially if given repeatedly (16) , could induce an undesirable inflammatory cytokine cascade. Nonetheless, from the perspective of treatment intended to activate macrophages, modulation of Th1 cell responses via costimulation pathways may well be an alternative to the administration of exogenous cytokines (23).
FIG. 9. Treatment with anti-CD40 or anti-CTLA-4 enhances effect of antimony (Sb) in wild-type BALB/c mice. Liver parasite burdens were determined 12 days after infection, and mice were then injected once with either control rat or hamster IgG or suboptimal anti-CD40 (0.1 mg) or anti-CTLA-4 (0.3 mg). Mice either were not treated further or received low-dose Sb on day 14. Liver burdens on day 21 were compared to day 14 levels (1,202 Ϯ 58 LDU; n ϭ 12) to determine percent parasite killing. Results are from two to three experiments with 7 to 12 mice per group. P is Ͻ0.05 for results with both anti-CD40 plus Sb and anti-CTLA-4 plus Sb versus (i) day 14 LDU value for untreated mice and (ii) day 21 results with all other indicated treatments. 
